

DESCRIPTION

NOVEL FUSION PROTEIN, GENE THEREOF,
RECOMBINANT VECTOR BEARING THE GENE
AND RECOMBINANT VIRUS AS WELL AS USE THEREOF

TECHNICAL FIELD

The present invention relates to a novel fusion polypeptide of a polypeptide having the antigenicity of Mycoplasma gallisepticum and a polypeptide derived from
5 the outer membrane protein of herpes viruses, a hybrid DNA coding for the fusion polypeptide, and a recombinant Avipox virus bearing the hybrid DNA, as well as a vaccine using the recombinant Avipox virus.

BACKGROUND ART

10 Mycoplasma gallisepticum (hereinafter sometimes abbreviated as MG) is a bacterium that causes reduction in an egg-laying rate and a hatching rate of eggs for poultry including chicken. This causative MG is widely spread all over the world so that a great deal of damage
15 has been done to the poultry farming. For the prevention of MG, an inactivated vaccine or a live vaccine is currently utilized. However, the former live vaccine involves disadvantages of complicated inoculation procedures, short duration of immunity, expensive etc.
20 The latter vaccine has such a defect that an unexpected

disease might be developed by use in combination with live vaccine for other disease. Another disadvantage is that MG agglutination reaction system, which makes rapid detection of MG infection possible, can not be used for
5 both inactivated and live vaccines.

It is expected that a protein derived from MG such as its antigenic protein for preventing from MG infection would be produced by genetic engineering technology and utilized as a vaccine.

10 The production system of the antigenic protein of Mycoplasma gallisepticum using E. coli or yeast by means of genetic engineering (JPA 2-111795, etc.) encounters such problems that depending upon a protein to be expressed, the antigenic protein is only expressed in
15 a less amount, proteins of host origin might be by-produced and intermingled, host-derived pyrogen is removed only with difficulty, etc. For these reasons, studies are still focused on a recombinant virus to prepare antigenic proteins or on a recombinant live
20 vaccine.

The expression of foreign genes using recombinant viruses, in most cases, genes of eucaryotes or viral genes are expressed. For this reason, addition or expression mode of sugar chains or the like is similar
25 to the protein expression mechanism in infected cells. Thus, induction of an antibody titer to the expressed protein was relatively easy in vivo. However, genes of prokaryotes are rarely expressed in recombinant viruses.

Because of different expression mode between eukaryotes and prokaryotes, it was difficult to say that a specific antibody was effectively induced (Austen et al., Protein Targeting and Selection, Oxford Univ. Press (1991)).

5 Turning to MG, recombinant viruses in which a gene coding for the protein has been incorporated are known by JPA 5-824646 and JPA 7-133295, WO 94/23019, etc. In particular, WO 94/23019 reveals that when a recombinant virus capable of expressing the antigenic
10 protein of MG having a viral membrane anchoring region, which is obtained by ligating the signal membrane anchoring portion of HN gene of New Castle disease virus (hereinafter abbreviated as NDV) with the antigenic gene of MG, is inoculated as a recombinant live vaccine, the
15 antibody is induced more effectively than a recombinant virus capable of expressing the antigenic gene of MG alone.

 However, expression to such an extent is not always sufficient to achieve the desired effect as a
20 vaccine.

 Therefore, it is the urgent need to find an improved method for higher recognition of the antigen in order to develop an effective vaccine against MG infections.

25 Outer membrane proteins other than NDV mentioned above are known also in the genus Herpesvirus, etc. With respect to glycoproteins B(gB), C(gC), D(gD), H(gH) and I(gI) of herpes simplex viruses; proteins gBh,

gCh, gDh, gHh and gIh of Marek's disease viruses
(hereinafter often referred to as MDV) corresponding to
herpes simplex virus glycoproteins gB, gC, gD, gH and gI
and proteins of the genus Herpesvirus homologous to those
5 proteins described above, etc., the nucleotide sequence
and amino acid sequence of these proteins are known. It
is also known that a part of these proteins induces
neutralizing antibodies of herpes simplex viruses (Deluca
et al., Virology, 122, 411-423 (1982)). It is further
10 known that neutralizing antibodies can be induced by
incorporating genes coding for these proteins into
vaccinia viruses and expressing the genes (Blacklaws et
al., Virology, 177, 727-736 (1990)).

However, investigations to make use of signal
15 sequences of such outer membrane proteins of the genus
Herpesvirus were hardly made so far.

DISCLOSURE OF THE INVENTION

Under the situation of the prior art stated
above, the present inventors have made extensive studies
20 to provide a recombinant virus capable of expressing a
Mycoplasma antigenic protein having an enhanced infection
prevention activity in large quantities, which allows a
host to recognize the antigen highly efficiently. As a
result, it has been found that by infecting to a host a
25 recombinant Avipox virus, in which a hybrid DNA obtained
by ligating a DNA of the outer membrane protein of the
genus Herpesvirus with a DNA of the antigenic protein of

Mycoplasma has been inserted, the antigen recognizing ability of the host can be markedly improved. The present invention has thus been accomplished.

Accordingly, the present invention provides:

- 5 a fusion protein comprising a polypeptide having the antigenicity of Mycoplasma gallisepticum (hereinafter sometimes referred to as Mycoplasma-derived polypeptide) and a polypeptide derived from the outer membrane protein of a herpes virus (hereinafter sometimes referred to as Herpesvirus-derived polypeptide)
- 10 characterized in that the polypeptide derived from outer membrane protein is ligated with the polypeptide having the antigenicity of Mycoplasma gallisepticum at the N terminus thereof;
- 15 a hybrid DNA coding for the fusion protein;
a recombinant Avipox virus in which the hybrid DNA has been incorporated; and,
a live vaccine comprising the recombinant Avipox virus as an effective ingredient.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a drawing for explaining procedures for construction of pNZ40K-S.

Fig. 2 is a drawing for explaining procedures for construction of pNZ40K-S.

25 Fig. 3 is a drawing for explaining procedures for construction of pNZ40K-S.

Fig. 4 is a drawing for explaining procedures

for construction of pNZ40K-C.

Fig. 5 is a drawing for explaining procedures for construction of pNZ40K-C.

Fig. 6 is a drawing for explaining procedures
5 for construction of pNZ40K-C.

Fig. 7 shows the results of Western blotting by which expression of TTM-1 polypeptide was confirmed.

Fig. 8 shows scores of the tracheal lesion caused.

10 BEST MODE FOR PRACTICING THE INVENTION

Mycoplasma-derived polypeptides and genes therefor

In the present invention, the term Mycoplasma-derived polypeptides is used to mean the antigenic proteins that cause an antigen-antibody reaction with MG
15 immune serum or MG infected serum and that are derived from MG. These polypeptides are not restricted to proteins per se that native Mycoplasma gallisepticum expresses, and may include modified polypeptides. For example, one or more amino acids of the polypeptides may
20 be modified naturally or artificially in a conventional manner such as site-specific mutation, etc. (JPB 6-16709, etc.) through loss, addition, insertion, deletion, substitution, etc. Of course, the proteins, even after such modification, should contain the epitope showing the
25 antigenicity. For determination of the epitope region, there are available known methods based on the peptide scanning technique such as the method of Geysen et al.

(J. Immunol. Meth., 102, 259-274 (1987)), the method of Hopp et al., (Proc. Natl. Acad. USA, 78, 3824-3828 (1981)), the method Chou et al. (Advances in Enzymology, 47, 145-148 (1987)), etc.

5 Specific examples of the peptides having the antigenicity include antigenic proteins disclosed in JPA 2-111795 (U.S. Patent Application Serial Nos. 359,779, 07/888,320 and 08/299,662), JPA 5-824646 (U.S. Patent No. 5,489,430), WO 94/23019 (U.S. Patent Application Serial
10 No. 08/525,742, JPA 6-521927) and proteins of Mycoplasma gallisepticum containing the amino acid sequences of those proteins. Of course, so long as the epitope is contained therein, a part of the peptides described above may also be usable.

15 Of these peptides, preferred are the polypeptide of about 40 kilodaltons (kd) described in JPA 5-824646, the polypeptide of about 66 kd encoded by TM-66 gene and the polypeptide of about 67 kd encoded by TM-67 gene described in JPA 5-521927, which are
20 designated as SEQ NO: 16 and SEQ NO: 27 therein.

 In the present invention, genes of the Mycoplasma-derived polypeptides bear DNA sequences coding for the polypeptide having the antigenicity of Mycoplasma gallisepticum described above. Such DNA can be obtained
25 by synthesis or acquired from wild bacteria belonging to Mycoplasma gallisepticum. Specific examples of such bacteria are strains R, S6, KP-13, PG31, etc. DNA may also be derived from MG isolated from wild strains.

These genes can also be modified by loss, addition, insertion, deletion, substitution, etc. in a conventional manner as described in Methods in Enzymology, etc.

Herpesvirus-derived polypeptides and genes thereof

5 The Herpesvirus-derived polypeptides in the present invention refer to polypeptides derived from proteins that construct an envelope of viruses belonging to the genus Herpesvirus. The Herpesvirus-derived polypeptides may not always be the full length of the
10 proteins. Where the polypeptides are used solely to be expressed on the surface of cell membranes function as fusion proteins, it is sufficient for the polypeptide to contain a membrane anchor and a signal sequence therein, and where the polypeptides are employed for secretion,
15 the polypeptides may contain only a signal sequence for that purpose. The outer membrane proteins may be either type I or type II of the outer membrane proteins. The signal sequence and the membrane anchoring sequence are both readily detectable by analyzing the amino acid
20 sequence in the hydrophobic peptide region at the carboxyl terminus or amino terminus thereof.

Specific examples of the outer membrane protein include gB, gC, gD, gH and gI which are glycoproteins of herpes simplex viruses, and gBh, gCh, gDh, gHh and gIh of
25 MDV corresponding to herpes simplex viruses glycoproteins gB, gC, gD, gH and gI, and proteins of the genus Herpesvirus homologous to the proteins described above.

Of course, polypeptides bearing the epitope other than the signal sequence of the outer membrane proteins may also be ligated with the aforesaid polypeptides having the antigenicity. By the ligation it
5 is expected that the epitope will give the immunity to the living body in vivo.

In the present invention, the genes for the Mycoplasma-derived polypeptides contain DNA sequences coding for the Herpesvirus-derived polypeptides described
10 above and such DNAs can be synthesized or acquired from naturally occurring herpes viruses. These genes may also be modified by loss, addition, insertion, deletion, substitution, etc. in a conventional manner as described in Methods in Enzymology, etc.

15 Fusion protein and hybrid DNA

The fusion proteins of the present invention are obtained by incubating a recombinant Avipox virus inserted hybrid DNA, which will be later described, in culture cells such as chick embryo fibroblast cells
20 (hereinafter referred to as CEF cells) or embryonated chorioallantoic membrane cells, etc.

The thus obtained fusion proteins can be employed as a component vaccine.

The hybrid DNA of the present invention
25 comprises the gene for the Mycoplasma-derived polypeptide and the gene for the Herpesvirus-derived polypeptide, which are ligated with each other directly or via an

optional DNA sequence.

The hybrid DNA of the present invention can be produced in a conventional manner, for example, by a method in which the outer membrane protein and the
 5 antigenic protein of Mycoplasma gallisepticum are digested with restriction enzymes, respectively, and the resulting ligatable DNA fragment coding for the outer membrane protein of herpes viruses or for the signal
 10 the resulting ligatable DNA fragment coding for the antigenic protein of Mycoplasma gallisepticum, using a ligase directly or via an appropriate linker.

Specific examples of the amino acid sequences for the fusion proteins of the present invention include
 a 15 SEQ^{ID}_^ NO: 2 and SEQ^{ID}_^ NO: 4. The sequence of the antigenic protein of 40 kilodaltons derived from Mycoplasma gallisepticum is found in amino acids 64-456 of SEQ NO: 2
 a and in amino acids 693-1086 of SEQ^{ID}_^ NO: 4. The signal sequence of outer membrane protein gB derived from MDV is
 a 20 found in amino acids 1-63 of SEQ^{ID}_^ NO: 2. In SEQ^{ID}_^ NO: 4, amino acids 1-672 correspond to almost the full length of outer membrane protein gB derived from MDV. Specific examples of nucleotide sequences of the hybrid DNAs
 a coding for these fusion proteins are those shown by SEQ^{ID}_^
 a 25 NO: 1 and SEQ^{ID}_^ NO: 3.

These fusion proteins and hybrid DNAs are given by way of examples but are not deemed to be limited thereto.

Recombinant Avipox virus

The recombinant Avipox virus of the present invention is a recombinant Avipox virus in which the aforesaid DNA or hybrid DNA has been inserted in the non-essential region. The recombinant Avipox virus of the present invention can be constructed in a conventional manner, e.g., by the method described in Japanese Patent Application Laid-Open No. 1-168279. That is, the non-essential region of Avipox virus is incorporated into a DNA fragment to construct a first recombinant vector.

As the non-essential region of Avipox virus which is used in the present invention, there are a TK gene region of quail pox virus, a TK region of turkey pox virus and DNA fragments described in JPA 1-168279, preferably a region which causes homologous recombination with EcoRI fragment of about 7.3 Kb, HindIII fragment of about 5.2 Kb, EcoRI-HindIII fragment of about 5.0 Kb, BamHI fragment of about 4.0 Kb, described in the patent specification supra.

Examples of the vector used in the present invention include plasmids such as pBR322, pBR325, pBR327, pBR328, pUC7, pUC8, pUC9, pUC18, pUC19, and the like; phages such as λ phage, M13 phage, etc.; cosmid such as pH79 and the like.

The Avipox virus used in the present invention is not particularly limited so long as it is a virus infected to avian. Specific examples of such a virus include pigeon pox virus, fowl pox virus (hereafter

abbreviated as FPV), canary pox virus, turkey pox virus, preferably pigeon pox virus, FPV and turkey pox virus, more preferably pigeon pox virus and FPV. Specific examples of the most preferred Avipox virus include FPVs
5 such as ATCC VR-251, ATCC VR-249, ATCC VR-250, ATCC VR-229, ATCC VR-288, Nishigahara strain, Shisui strain, CEVA strain and a viral strain among CEVA strain-derived viruses which forms a large plaque when infected to chick embryo fibroblast, and a virus such as NP strain (chick
10 embryo-attenuated pigeon pox virus Nakano strain), etc. which is akin to FPV and used as a fowlpox live vaccine strain. These strains are commercially available and readily accessible.

Next, the hybrid DNA of the present invention
15 is inserted into the non-essential region of the first recombinant vector described above to construct a second recombinant vector. In general, the hybrid DNA employed may have any nucleotide sequence, irrespective of synthetic or natural one, so long as the hybrid DNA
20 effectively functions as a promoter in the system of transcription possessed by Avipox viruses. Accordingly, not only promoters inherent to Avipox viruses such as promoters for Avipox virus-derived genes coding for thymidine kinase but also DNAs derived from viruses other
25 than Avipox viruses and DNAs derived from eukaryotes or prokaryotes may also be employed in the present invention, insofar as these substances meet the requirements described above. Specific examples of such

promoters include promoters for vaccinia viruses (hereinafter often referred to as VV) as described in Journal of Virology, 51, 662-669 (1984), more specifically, a promoter of VV gene coding for 7.5 K polypeptide, a promoter of VV gene coding for 19 K polypeptide, a promoter of VV gene coding for 42 K polypeptide, a promoter of VV gene coding for thymidine kinase, a promoter of VV gene coding for 28 K polypeptide, etc. Furthermore, there may be used a synthetic promoter obtained by modification of the Moss et al. method (J. Mol. Biol., 210, 49-76 and 771-784, 1989), Davidson's synthetic promoter, a promoter obtained by modifying a part of the Davidson's promoter through deletion or change in such a range that the promoter activity is not lost (e.g.,

TTTTTTTTTTTTTGGCATATAAATAATAAATACAATAATTAATTACGCGTAAAAA
 a TTGAAAAACTATTCTAATTTATTGCACTC, (Seq ID NO:5)
 TTTTTTTTTTTTTTTTTTTTTTTTTTGGCATATAAATAATAAATACAATAATTAATTACGCGT
 a AAAAATTGAAAAACTATTCTAATTTATTGCACTC etc.). (Seq ID NO:6)

20 Further in view of easy detection of the recombinant virus, a marker gene such as a DNA coding for β -galactosidase may also be inserted.

The recombinant Avipox virus can be constructed by transfecting the second recombinant vector described above to animal culture cells, which has been previously
 25 infected with Avipox virus, and causing homologous recombination between the vector DNA and the viral genome DNA. The animal culture cells used herein can be any

cells, so long as Avipox can grow in the cells. Specific examples of such animal culture cells are CEF cells, embryonated egg chorioallantoic membrane cells, and the like.

- 5 The objective recombinant Avipox virus is isolated from the virus infected to host cells by plaque hybridization, etc.

Live vaccine

- The recombinant virus of the present invention
10 constructed by the method described above can be inoculated to avian as a live vaccine for Mycoplasma gallisepticum infection.

- The live vaccine of the present invention is prepared by, e.g., the following method, though the
15 process is not particularly limited thereto. The recombinant virus of the present invention is infected to cells in which the virus can grow (hereafter referred to as host cells). After the recombinant virus grows, the cells are recovered and homogenated. The homogenate is
20 centrifuged to separate into the precipitates and the high titer supernatant containing the recombinant virus. The resulting supernatant is substantially free of host cells but contains the cell culture medium and the
25 vaccine. The supernatant may be diluted by adding a pharmacologically inert carrier, e.g., physiological saline, etc. The supernatant may be freeze-dried to be provided for use as a live vaccine. A method for

administration of the live vaccine of the present invention to fowl is not particularly limited and examples of the administration include a method for scratching the skin and inoculating the live vaccine on the scratch, effecting the inoculation through injection, oral administration by mixing the live vaccine with feed or drinking water, inhalation by aerosol or spray, etc. In order to use as the live vaccine, the dosage may be the same as ordinary live vaccine; for example, approximately 10^2 to 10^8 plaque forming unit (hereinafter abbreviated as PFU) is inoculated per chick. Where the inoculation is effected by injection, the recombinant virus of the present invention is generally suspended in about 0.1 ml of an isotonic solvent such as physiological saline and the resulting suspension is provided for use. The live vaccine of the present invention can be lyophilized under ordinary conditions and can be stored at room temperature. It is also possible to freeze the virus suspension at -20 to -70°C and store the frozen suspension.

Particularly where the genes coding for the polypeptides derived from the outer membrane proteins of herpes viruses described above are those coding for polypeptides having more than one epitope of herpes viruses, preferably having at least 90% homology to native outer membrane proteins, the live vaccine of the present invention functions as a vaccine for both Mycoplasma gallisepticum infection and Avipox viral

infection. In addition, the live vaccine of the present invention can also function as an effective vaccine for infection with herpes virus originating from outer membrane proteins. That is, the live vaccine of the present invention can be used as a so-called trivalent vaccine.

EXAMPLES

Example 1

Construction of recombinant pNZ40K-S bearing hybrid DNA ligating TTM-1 protein DNA immediately after the signal of gB gene for Marek's disease virus (cf. Figs. 1, 2 and 3)

First, plasmid pUCgB bearing gB gene of Marek's disease virus, disclosed in JPA 6-78764, was digested with restriction enzymes BamHI and SalI to recover a fragment of 3.9 kb.

Separately, plasmid pGTPs was constructed by digesting plasmid pNZ1729R (Yanagida et al., J. Virol., 66, 1402-1408 (1992)) with HindIII and SalI, inserting the resulting DNA fragment of about 140 bp into pUC18 at the HindIII-SalI site thereof, further inserting synthetic DNA (5'-AGCTGCCCCCCCCGCAAGCTTGCA-3')^(SEQ ID NO:7) at the HindIII-PstI site, then inserting synthetic DNA (5'-TCGACATTTTATGTGTAC-3')^(SEQ ID NO:8) at the SalI-EcoRI site and finally inserting synthetic DNA (5'-AATCGGCCGGGGGGGCCAGCT-3')^(SEQ ID NO:9) at the SacI-EcoRI site.

The thus obtained pGTPs was digested with

restriction enzymes SalI and BamHI and then ligated with the aforesaid 3.9 kb fragment using a ligase to obtain pGTPsMDgB. Thereafter, pNZ2929XM1 disclosed in WO 94/23019 was digested with EcoRI to recover a fragment of 740 bp and then obtained a blunt end with T4 DNA polymerase. On the other hand, pGTPsMDgB was also digested with XbaI and then obtained a blunt end with T4 DNA polymerase. Subsequently, pGTPsMDgB was ligated with the 740 bp fragment having the blunt end using a ligase to construct a new plasmid. This new plasmid was digested with BglII and SalI to recover a fragment of 3.0 kb. The 3.0 kb fragment was ligated with the 1.1 kb fragment obtained through digestion of pNZ2927XM1 with BglII and SalI, using a ligase. Thus, there was obtained a plasmid ligating the N terminus of TTM-1 gene at the C terminus of the signal sequence of gB gene of Marek's disease virus.

Finally, a fragment of 1.4 kb obtained by digestion of pGTPs40K-S with SalI and BamHI was ligated with a fragment of 9.3 kb obtained by digestion of plasmid pNZ1829R with SalII and BamHI, using a ligase. The objective plasmid pNZ40K-S of 10.7 kb was thus constructed for use in recombination.

Example 2

Construction of recombinant pNZ40K-C bearing hybrid DNA ligating TTM-1 protein DNA at the C terminus of gB gene for Marek's disease virus (cf. Figs. 4, 5 and 6)

After plasmid pGTPsMDgB obtained in Example 1 was digested with restriction enzyme MluI, and then obtained a blunt end with T4 DNA polymerase, which was followed by digestion with restriction enzyme XbaI to recover a fragment of 1.9 kb. Separately, pBluescriptII (made by Toyobo Co., Ltd., hereinafter abbreviated as pBSKSII) was digested with restriction enzymes XbaI and SmaI. The resulting fragment was ligated with the 1.9 kb fragment obtained above using a ligase to give a plasmid.

The resulting plasmid was digested with restriction enzymes EcoRI and SalI. The resulting fragment was ligated with the 550 bp fragment and the 615 bp fragment, both obtained by digestion of pNZ2929XM1 with restriction enzymes EcoRI and SalI and with restriction enzymes EcoT22I and SalI, respectively, using a ligase to construct a plasmid. The thus obtained plasmid was digested with restriction enzymes XbaI and SalI. The resulting 2.7 kb fragment was ligated with the 3.3 kb fragment obtained by digestion of pGTPsMDgB with restriction enzymes XbaI and SalI, using a ligase.

Plasmid pGTPs40K-C ligating the TTM-1 gene at the N terminus thereof with the gB gene for Marek's disease virus at the C terminus thereof was thus obtained.

Finally, a fragment of 2.7 kb obtained by digestion of pGTPs40K-C with SalI and XbaI was ligated with a fragment of 9.5 kb obtained by digestion of plasmid pNZ1829R with SalI and XbaI, using a ligase. The objective plasmid pNZ40K-C of 12.2 kb for recombination

was thus constructed.

Example 3

Construction of recombinants FPV 40K-C and 40K-S and purification thereof

- 5 NP strain, which is a fowlpox live vaccine strain, was infected to monolayered CEF at m.o.i. = 0.1. Three hours after, these cells were scraped off from the monolayer by a treatment with trypsin to form a cell suspension. After 2×10^7 cells in the suspension were
 10 mixed with 10 μ g of plasmid pNZ40K-C or pNZ40K-S for use in recombination, the mixture was suspended in Saline G (0.14 M sodium chloride, 0.5 mM potassium chloride, 1.1 mM disodium hydrogenphosphate, 1.5 mM potassium dihydrogenphosphate, 0.5 mM magnesium chloride
 15 hexahydrate, 0.011% glucose). The suspension was subjected to electrophoresis under conditions of 3.0 kV *GENE PULSER (trademark)* cm^{-1} , 0.4 msec and 25°C, using ~~Gene Pulser~~ (manufactured by Bio-Rad Co., Ltd.) at room temperature. The plasmid-infected cells were then cultured at 37°C for 72 hours.
 20 The cells were lysed by freezing and thawing 3 times to recover viruses containing the recombinant virus.

- The recovered recombinant virus was selected as follows. The recovered viral solution was infected to monolayered CEF and 10 ml of agar solution containing
 25 growth medium was overlaid thereon. After agar was warmed at room temperature, incubation was performed at 37°C until plaques of FPV appeared. Then agar medium

containing Blueo-gal in a concentration of 200 µg/ml was overlaid on the agar followed by incubation at 37°C for further 48 hours. Among all of the plaques, about 1% of the plaques were colored blue. These blue plaques were isolated and recovered. By the same procedures, isolation and recovery were repeated to purify the virus until all the plaques were stained to blue. In general, the repeated procedures were terminated by 3 to 4 days. The purified strains were named 40K-C and 40K-S, respectively. In 40K-C and 40K-S, each position of the DNAs inserted was confirmed by dot blotting hybridization and Southern blotting hybridization.

Example 4

Expression of TTM-1 polypeptide in cells infected with 40K-C and 40K-S

In order to confirm that 40K-C and 40K-S could express TTM-1 polypeptide in infected cells, Western blotting was performed using anti-Mycoplasma gallisepticum S6 strain sera. Virus 40K-C or 40K-S was infected to CEF and cultured at 37°C until plaques were formed. The cells were then scraped off with a cell scraper and centrifuged at 8000G for 20 minutes together with the culture supernatant. The cell-containing precipitates (hereinafter referred to as pellets) were recovered. After washing with PBS, the pellets were centrifuged at 8000G for 20 minutes followed by rinsing to recover the pellets. The pellets were then suspended

in 150 μ l of PBS. From the suspension 50 μ l was taken and added with the same volume of Laemmli's buffer (containing 10% mercapto-ethanol). After boiling for 3 minutes, the mixture was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (hereinafter abbreviated as SDS-PAGE) in accordance with the Laemmli's method (Nature, 227, 668-685 (1970)). The polypeptides isolated on the SDS-PAGE-completed gel were transferred onto a polyvinylidene difluoride membrane (~~Immobilon~~ ^{IMMOBILON (trademark)} Transfer Membrane, made by Millipore Inc., hereinafter simply referred to as membrane) according to the method of Burnett et al., (A. Anal. Biochem., 112, 195-203 (1970)) or by the method of Towbin et al. (Proc. Natl. Acad. Sci., 75, 4350-4354 (1979)) by means of electrophoresis. The membrane was dipped for an hour into PBS containing 3% skimmed milk for blocking not to cause any non-specific binding. Next, the membrane was dipped for an hour in PBS in which chick anti-Mycoplasma gallisepticum S6 strain serum was diluted to 1000-fold.

Subsequently, the membrane was rinsed with PBS and then dipped for an hour in PBS containing alkaline phosphatase conjugate anti-chick IgG as a secondary antibody. After the membrane was rinsed with PBS, a color-forming reaction was carried out in 10 ml of a solution containing 100 mM Tris hydrochloride (pH 7.5), 0.15 M sodium chloride and 50 mM magnesium chloride, using Nitro Blue Tetrazolium salt (NBT, made by GIBCO-BRL Inc.) and 5-bromo-4-chloro-3-indole phosphate-p-toluidine

(BCIP, made by GIBCO-BRL Inc.) as color-forming substrates.

The results of the Western blotting are shown in Fig. 7.

5 As shown in Fig. 7, proteins could be confirmed with the cells infected both with 40K-S and 40K-C as those reactive at the objective positions. It was thus verified that the expected proteins could be expressed in the recombinant FPV infected cells.

10 Example 5

Antibody-inducing capability of recombinant FPV-inoculated chicken

After 40K-C and 40K-S were cultured in CEF at 37°C for 48 hours, the procedure of freezing and thawing
 15 was repeated twice to recover the cell suspension. The cell suspension was adjusted to have a virus titer of 10^6 pfu/ml and then inoculated to SPF chicken (Line M, Nippon Seibutsu Kagaku Kenkyusho) of 7 days old at the right wing web in a dose of 10 μ l through a stab needle. After
 20 the inoculation, take of the pock was observed and the sera were collected 2 weeks after the inoculation. The antibody titer of the sera collected was determined by
 a (Enzyme Linked Immunosorbent Assay) ELISA. The purified TTM-1 polypeptide was dissolved in a bicarbonate buffer solution in a concentration of 1
 25 μ g/well. After adsorption to a 96 well microtiter plate, blocking was effected with skimmed milk to prevent the subsequent non-specific adsorption. Next, a dilution of

the sample serum was charged in each well and then horse
 radish peroxide-labeled anti-chicken immunoglobulin
 antibody (rabbit antibody) was added thereto as a
 secondary antibody. After thoroughly washing, 2,2'-
 5 azinodiethylbenzothiazoline sulfonate was added to the
 mixture as a substrate and a relative dilution
 magnification of the antibody was measured with an
 immuno-reader in terms of absorbance at a wavelength of
 405 nm. As a primary antibody for control, anti-TTM-1
 10 polypeptide chicken serum was used. The results are
 shown in Table 1.

Table 1. Antibody titer of rFPV-inoculated
 chicken by ELISA

15	Methods for treating chicken	Antibody titer of anti- TTM-1 polypeptide
	40K-S inoculation	1024
	40K-C inoculation	512
	TTM-1 immunization	512
	non-inoculated	1

20 Antibody titer: Dilution magnification when the
 antibody titer of the group of non-
 inoculated chicken serum dilution was
 made 1

As shown in Table 1, the results reveal that
 25 when 40K-C or 40K-S was inoculated to chicken, the anti-
 TTM-1 antibody titer in sera was increased to the level

higher than the antibody titer in sera from the chicken immunized with TTM-1 polypeptide. From the results it was confirmed that the recombinant FPV could significantly induce the antibody titer to the inoculated chicken.

Example 6

Mycoplasma challenge test against recombinant FPV-inoculated chicken

The challenge test was conducted basically in accordance with the standard for biological preparations for animals. The method is briefly described below.

Strains 40K-C and 40K-S were inoculated to SPF chicken (Line M, Japan Biological Science Laboratory) of 5 weeks old at the right wing web in a dose of 10 μ l through a stab needle. After the inoculation, take of the pock was observed to verify completion of the immunization. Two weeks after the inoculation, Mycoplasma gallisepticum strain R was forced to be intratracheally administered in a dose of 10^4 to 10^5

cfu/chick, whereby infection was made sure. On Day 14 after the infection, the chicken were euthanized with

a NEMBITAL (trade name) (manufactured by Abbott) Nembutal. Tissue sections were prepared from the tracheal lesion and scores of the tracheal lesion were determined based on the thickness of tracheal mucous membrane and histological findings. The scores were also determined by the above standard for biological preparations. An average of scores for the tracheal

[illegible][illegible][illegible]

The results of evaluation are shown in Table 3 and Fig. 8.

Table 3. Means tracheal lesion scores in FPV-inoculated Chicken

Vaccination	Lesion Score	
	Average	Standard Error
40K-S	1.38	0.16
40K-C	1.89	0.13
Commercial vaccine	2.11	0.24
TTM-1 polypeptide	1.09	0.23
None	2.27	0.21

As is clearly noted from the results above, the lesion scores of chicken inoculated with 40K-C and 40K-S are obviously low as compared to that of the non-inoculated chicken, indicating that the vaccines of the present invention clearly imparted to chicken the effective infection prevention for Mycoplasma challenge. Thus, the results reveal that 40K-C and 40K-S could be effective vaccines for Mycoplasma gallisepticum.

INDUSTRIAL APPLICABILITY

According to the present invention, the fusion proteins of the polypeptides derived from antigenic proteins of Mycoplasma gallisepticum and the polypeptides
5 derived from outer membrane proteins of herpes viruses are obtained. The fusion proteins are effective as vaccines for anti-Mycoplasma infection, anti-chicken pox or anti-Marek's disease. By use of the hybrid DNAs coding for the fusion proteins, Mycoplasma gallisepticum
10 antigenic proteins can be efficiently provided on the surface of host cells. Moreover, the hybrid DNAs can secrete the antigenic proteins extracellularly to obtain Avipox viruses that can be efficiently recognized by the antigen recognizing cells in host cells. The thus
15 obtained recombinant Avipox viruses are useful as potent vaccines for anti-Mycoplasma infection.

Sequence :

ATG CAC TAT TTT AGG CGG AAT TGC ATA TTT TTC CTT ATA GTT ATT CTA	48
Met His Tyr Phe Arg Arg Asn Cys Ile Phe Phe Leu Ile Val Ile Leu	
1 5 10 15	
TAT GGT ACG AAC TCA TCT CCG AGT ACC CAA AAT GTG ACA TCA AGA GAA	96
Tyr Gly Thr Asn Ser Ser Pro Ser Thr Gln Asn Val Thr Ser Arg Glu	
20 25 30	

	GTT GTT TCG AGC GTC CAG TTG TCT GAG GAA GAG TCT ACG TTT TAT CTT	144
	Val Val Ser Ser Val Gln Leu Ser Glu Glu Glu Ser Thr Phe Tyr Leu	
	35 40 45	
	TGT CCC CCA CCA GTG GGT TCA ACC GTG ATC CGT CTA GAA TTC GGC TGT	192
5	Cys Pro Pro Pro Val Gly Ser Thr Val Ile Arg Leu Glu Phe Gly Cys	
	50 55 60	
	ATG TCT ATT ACT AAA AAA GAT GCA AAC CCA AAT AAT GGC CAA ACC CAA	240
	Met Ser Ile Thr Lys Lys Asp Ala Asn Pro Asn Asn Gly Gln Thr Gln	
	65 70 75 80	
10	TTA GAA GCA GCG CGA ATG GAG TTA ACA GAT CTA ATC AAT GCT AAA GCG	288
	Leu Glu Ala Ala Arg Met Glu Leu Thr Asp Leu Ile Asn Ala Lys Ala	
	85 90 95	
	ATG ACA TTA GCT TCA CTA CAA GAC TAT GCC AAG ATT GAA GCT AGT TTA	336
	Met Thr Leu Ala Ser Leu Gln Asp Tyr Ala Lys Ile Glu Ala Ser Leu	
15	100 105 110	
	TCA TCT GCT TAT AGT GAA GCT GAA ACA GTT AAC AAT AAC CTT AAT GCA	384
	Ser Ser Ala Tyr Ser Glu Ala Glu Thr Val Asn Asn Asn Leu Asn Ala	
	115 120 125	
	ACA TTA GAA CAA CTA AAA ATG GCT AAA ACT AAT TTA GAA TCA GCC ATC	432
20	Thr Leu Glu Gln Leu Lys Met Ala Lys Thr Asn Leu Glu Ser Ala Ile	
	130 135 140	
	AAC CAA GCT AAT ACG GAT AAA ACG ACT TTT GAT AAT GAA CAC CCA AAT	480
	Asn Gln Ala Asn Thr Asp Lys Thr Thr Phe Asp Asn Glu His Pro Asn	
	145 150 155 160	
25	TTA GTT GAA GCA TAC AAA GCA CTA AAA ACC ACT TTA GAA CAA CGT GCT	528
	Leu Val Glu Ala Tyr Lys Ala Leu Lys Thr Thr Leu Glu Gln Arg Ala	
	165 170 175	

ACT AAC CTT GAA GGT TTG TCA TCA ACT GCT TAT AAT CAA ATT CGC AAT 576
 Thr Asn Leu Glu Gly Leu Ser Ser Thr Ala Tyr Asn Gln Ile Arg Asn
 180 185 190
 AAT TTA GTG GAT CTA TAC AAT AAA GCT AGT AGT TTA ATA ACT AAA ACA 624
 5 Asn Leu Val Asp Leu Tyr Asn Lys Ala Ser Ser Leu Ile Thr Lys Thr
 195 200 205
 CTA GAT CCA CTA AAT GGG GGA ACG CTT TTA GAT TCT AAT GAG ATT ACT 672
 Leu Asp Pro Leu Asn Gly Gly Thr Leu Leu Asp Ser Asn Glu Ile Thr
 210 215 220
 10 ACA GCT AAT AAG AAT ATT AAT AAT ACG TTA TCA ACT ATT AAT GAA CAA 720
 Thr Ala Asn Lys Asn Ile Asn Asn Thr Leu Ser Thr Ile Asn Glu Gln
 225 230 235 240
 AAG ACT AAT GCT GAT GCA TTA TCT AAT AGT TTT ATT AAA AAA GTG ATT 768
 Lys Thr Asn Ala Asp Ala Leu Ser Asn Ser Phe Ile Lys Lys Val Ile
 15 245 250 255
 CAA AAT AAT GAA CAA AGT TTT GTA GGG ACT TTT ACA AAC GCT AAT GTT 816
 Gln Asn Asn Glu Gln Ser Phe Val Gly Thr Phe Thr Asn Ala Asn Val
 260 265 270
 CAA CCT TCA AAC TAC AGT TTT GTT GCT TTT AGT GCT GAT GTA ACA CCC 864
 20 Gln Pro Ser Asn Tyr Ser Phe Val Ala Phe Ser Ala Asp Val Thr Pro
 275 280 285
 GTC AAT TAT AAA TAT GCA AGA AGG ACC GTT TGG AAT GGT GAT GAA CCT 912
 Val Asn Tyr Lys Tyr Ala Arg Arg Thr Val Trp Asn Gly Asp Glu Pro
 290 295 300
 25 TCA AGT AGA ATT CTT GCA AAC ACG AAT AGT ATC ACA GAT GTT TCT TGG 960
 Ser Ser Arg Ile Leu Ala Asn Thr Asn Ser Ile Thr Asp Val Ser Trp
 305 310 315 320

00447052-040599

	ATT TAT AGT TTA GCT GGA ACA AAC ACG AAG TAC CAA TTT AGT TTT AGC	1008
	Ile Tyr Ser Leu Ala Gly Thr Asn Thr Lys Tyr Gln Phe Ser Phe Ser	
	325 330 335	
	AAC TAT GGT CCA TCA ACT GGT TAT TTA TAT TTC CCT TAT AAG TTG GTT	1056
5	Asn Tyr Gly Pro Ser Thr Gly Tyr Leu Tyr Phe Pro Tyr Lys Leu Val	
	340 345 350	
	AAA GCA GCT GAT GCT AAT AAC GTT GGA TTA CAA TAC AAA TTA AAT AAT	1104
	Lys Ala Ala Asp Ala Asn Asn Val Gly Leu Gln Tyr Lys Leu Asn Asn	
	355 360 365	
10	GGA AAT GTT CAA CAA GTT GAG TTT GCC ACT TCA ACT AGT GCA AAT AAT	1152
	Gly Asn Val Gln Gln Val Glu Phe Ala Thr Ser Thr Ser Ala Asn Asn	
	370 375 380	
	ACT ACA GCT AAT CCA ACT CCA GCA GTT GAT GAG ATT AAA GTT GCT AAA	1200
	Thr Thr Ala Asn Pro Thr Pro Ala Val Asp Glu Ile Lys Val Ala Lys	
15	385 390 395 400	
	ATC GTT TTA TCA GGT TTA AGA TTT GGC CAA AAC ACA ATC GAA TTA AGT	1248
	Ile Val Leu Ser Gly Leu Arg Phe Gly Gln Asn Thr Ile Glu Leu Ser	
	405 410 415	
	GTT CCA ACG GGT GAA GGA AAT ATG AAT AAA GTT GCG CCA ATG ATT GGC	1296
20	Val Pro Thr Gly Glu Gly Asn Met Asn Lys Val Ala Pro Met Ile Gly	
	420 425 430	
	AAC ATT TAT CTT AGC TCA AAT GAA AAT AAT GCT GAT AAG ATC CCC GGG	1344
	Asn Ile Tyr Leu Ser Ser Asn Glu Asn Asn Ala Asp Lys Ile Pro Gly	
	435 440 445	
25	TAC CGT CGA CCC GGT ACA TTT TTA TAA	1371
	Tyr Arg Arg Pro Gly Thr Phe Leu ***	
	450 455	

SEQUENCE LISTING

SEQ NO: 2

Length of sequence: 456

Type of sequence: amino acid

5 Topology: linear

Kind of sequence: protein

Sequence:

Met	His	Tyr	Phe	Arg	Arg	Asn	Cys	Ile	Phe	Phe	Leu	Ile	Val	Ile	Leu
1				5					10					15	
Tyr	Gly	Thr	Asn	Ser	Ser	Pro	Ser	Thr	Gln	Asn	Val	Thr	Ser	Arg	Glu
			20					25					30		
Val	Val	Ser	Ser	Val	Gln	Leu	Ser	Glu	Glu	Glu	Ser	Thr	Phe	Tyr	Leu
		35				40						45			
Cys	Pro	Pro	Pro	Val	Gly	Ser	Thr	Val	Ile	Arg	Leu	Glu	Phe	Gly	Cys
	50					55					60				
Met	Ser	Ile	Thr	Lys	Lys	Asp	Ala	Asn	Pro	Asn	Asn	Gly	Gln	Thr	Gln
	65				70					75					80
Leu	Glu	Ala	Ala	Arg	Met	Glu	Leu	Thr	Asp	Leu	Ile	Asn	Ala	Lys	Ala
				85					90					95	
Met	Thr	Leu	Ala	Ser	Leu	Gln	Asp	Tyr	Ala	Lys	Ile	Glu	Ala	Ser	Leu
		100						105					110		
Ser	Ser	Ala	Tyr	Ser	Glu	Ala	Glu	Thr	Val	Asn	Asn	Asn	Leu	Asn	Ala
		115						120					125		
Thr	Leu	Glu	Gln	Leu	Lys	Met	Ala	Lys	Thr	Asn	Leu	Glu	Ser	Ala	Ile
		130				135						140			
Asn	Gln	Ala	Asn	Thr	Asp	Lys	Thr	Thr	Phe	Asp	Asn	Glu	His	Pro	Asn
145						150					155				160

Leu Val Glu Ala Tyr Lys Ala Leu Lys Thr Thr Leu Glu Gln Arg Ala
 165 170 175
 Thr Asn Leu Glu Gly Leu Ser Ser Thr Ala Tyr Asn Gln Ile Arg Asn
 180 185 190
 Asn Leu Val Asp Leu Tyr Asn Lys Ala Ser Ser Leu Ile Thr Lys Thr
 195 200 205
 Leu Asp Pro Leu Asn Gly Gly Thr Leu Leu Asp Ser Asn Glu Ile Thr
 210 215 220
 Thr Ala Asn Lys Asn Ile Asn Asn Thr Leu Ser Thr Ile Asn Glu Gln
 225 230 235 240
 Lys Thr Asn Ala Asp Ala Leu Ser Asn Ser Phe Ile Lys Lys Val Ile
 245 250 255
 Gln Asn Asn Glu Gln Ser Phe Val Gly Thr Phe Thr Asn Ala Asn Val
 260 265 270
 Gln Pro Ser Asn Tyr Ser Phe Val Ala Phe Ser Ala Asp Val Thr Pro
 275 280 285
 Val Asn Tyr Lys Tyr Ala Arg Arg Thr Val Trp Asn Gly Asp Glu Pro
 290 295 300
 Ser Ser Arg Ile Leu Ala Asn Thr Asn Ser Ile Thr Asp Val Ser Trp
 305 310 315 320
 Ile Tyr Ser Leu Ala Gly Thr Asn Thr Lys Tyr Gln Phe Ser Phe Ser
 325 330 335
 Asn Tyr Gly Pro Ser Thr Gly Tyr Leu Tyr Phe Pro Tyr Lys Leu Val
 340 345 350
 Lys Ala Ala Asp Ala Asn Asn Val Gly Leu Gln Tyr Lys Leu Asn Asn
 355 360 365
 Gly Asn Val Gln Gln Val Glu Phe Ala Thr Ser Thr Ser Ala Asn Asn
 370 375 380

Sequence :

ATG CAC TAT TTT AGG CGG AAT TGC ATA TTT TTC CTT ATA GTT ATT CTA	48
Met His Tyr Phe Arg Arg Asn Cys Ile Phe Phe Leu Ile Val Ile Leu	
1 5 10 15	
TAT GGT ACG AAC TCA TCT CCG AGT ACC CAA AAT GTG ACA TCA AGA GAA	96
Tyr Gly Thr Asn Ser Ser Pro Ser Thr Gln Asn Val Thr Ser Arg Glu	
20 25 30	
GTT GTT TCG AGC GTC CAG TTG TCT GAG GAA GAG TCT ACG TTT TAT CTT	144
Val Val Ser Ser Val Gln Leu Ser Glu Glu Glu Ser Thr Phe Tyr Leu	
35 40 45	

TGT CCC CCA CCA GTG GGT TCA ACC GTG ATC CGT CTA GAA CCG CCG CGA 192
 Cys Pro Pro Pro Val Gly Ser Thr Val Ile Arg Leu Glu Pro Pro Arg
 50 55 60
 AAA TGT CCC GAA CCT AGA AAA GCC ACC GAG TGG GGT GAA GGA ATC GCG 240
 Lys Cys Pro Glu Pro Arg Lys Ala Thr Glu Trp Gly Glu Gly Ile Ala
 65 70 75 80
 ATA TTA TTT AAA GAG AAT ATC AGT CCA TAT AAA TTT AAA GTG ACG CTT 288
 Ile Leu Phe Lys Glu Asn Ile Ser Pro Tyr Lys Phe Lys Val Thr Leu
 85 90 95
 TAT TAT AAA AAT ATC ATT CAG ACG ACG ACA TGG ACG GGG ACG ACA TAT 336
 Tyr Tyr Lys Asn Ile Ile Gln Thr Thr Thr Trp Thr Gly Thr Thr Tyr
 100 105 110
 AGA CAG ATC ACT AAT CGA TAT ACA GAT AGG ACG CCC GTT TCC ATT GAA 384
 Arg Gln Ile Thr Asn Arg Tyr Thr Asp Arg Thr Pro Val Ser Ile Glu
 115 120 125
 GAG ATC ACG GAT CTA ATC GAC GGC AAA GGA AGA TGC TCA TCT AAA GCA 432
 Glu Ile Thr Asp Leu Ile Asp Gly Lys Gly Arg Cys Ser Ser Lys Ala
 130 135 140
 AGA TAC CTT AGA AAC AAT GTA TAT GTT GAA GCG TTT GAC AGG GAT GCG 480
 Arg Tyr Leu Arg Asn Asn Val Tyr Val Glu Ala Phe Asp Arg Asp Ala
 145 150 155 160
 GGA GAA AAA CAA GTA CTT CTA AAA CCA TCA AAA TTC AAC ACG CCC GAA 528
 Gly Glu Lys Gln Val Leu Leu Lys Pro Ser Lys Phe Asn Thr Pro Glu
 165 170 175
 TCT AGG GCA TGG CAC ACG ACT AAT GAG ACG TAT ACC GTG TGG GGA TCA 576
 Ser Arg Ala Trp His Thr Thr Asn Glu Thr Tyr Thr Val Trp Gly Ser
 180 185 190

0447052.040500
 0447052.040500
 0447052.040500

CCA TGG ATA TAT CGA ACG GGA ACC TCC GTC AAT TGT ATA GTA GAG GAA	624
Pro Trp Ile Tyr Arg Thr Gly Thr Ser Val Asn Cys Ile Val Glu Glu	
195 200 205	
ATG GAT GCC CGC TCT GTG TTT CCG TAT TCA TAT TTT GCA ATG GCC AAT	672
Met Asp Ala Arg Ser Val Phe Pro Tyr Ser Tyr Phe Ala Met Ala Asn	
210 215 220	
GGC GAC ATC GCG AAC ATA TCT CCA TTT TAT GGT CTA TCC CCA CCA GAG	720
Gly Asp Ile Ala Asn Ile Ser Pro Phe Tyr Gly Leu Ser Pro Pro Glu	
225 230 235 240	
GCT GCC GCA GAA CCC ATG GGA TAT CCC CAG GAT AAT TTC AAA CAA CTA	768
Ala Ala Ala Glu Pro Met Gly Tyr Pro Gln Asp Asn Phe Lys Gln Leu	
245 250 255	
GAT AGC TAT TTT TCA ATG GAT TTG GAC AAG CGT CGA AAA GCA AGC CTT	816
Asp Ser Tyr Phe Ser Met Asp Leu Asp Lys Arg Arg Lys Ala Ser Leu	
260 265 270	
CCA GTC AAG CGT AAC TTT CTC ATC ACA TCA CAC TTC ACA GTT GGG TGG	864
Pro Val Lys Arg Asn Phe Leu Ile Thr Ser His Phe Thr Val Gly Trp	
275 280 285	
GAC TGG GCT CCA AAA ACT ACT CGT GTA TGT TCA ATG ACT AAG TGG AAA	912
Asp Trp Ala Pro Lys Thr Thr Arg Val Cys Ser Met Thr Lys Trp Lys	
290 295 300	
GAG GTG ACT GAA ATG TTG CGT GCA ACA GTT AAT GGG AGA TAC AGA TTT	960
Glu Val Thr Glu Met Leu Arg Ala Thr Val Asn Gly Arg Tyr Arg Phe	
305 310 315 320	
ATG GCC CGT GAA CTT TCG GCA ACG TTT ATC AGT AAT ACG ACT GAG TTT	1008
Met Ala Arg Glu Leu Ser Ala Thr Phe Ile Ser Asn Thr Thr Glu Phe	
325 330 335	

GAT CCA AAT CGC ATC ATA TTA GGA CAA TGT ATT AAA CGC GAG GCA GAA	1056
Asp Pro Asn Arg Ile Ile Leu Gly Gln Cys Ile Lys Arg Glu Ala Glu	
340 345 350	
GCA GCA ATC GAG CAG ATA TTT AGG ACA AAA TAT AAT GAC AGT CAC GTC	1104
Ala Ala Ile Glu Gln Ile Phe Arg Thr Lys Tyr Asn Asp Ser His Val	
355 360 365	
AAG GTT GGA CAT GTA CAA TAT TTC TTG GCT CTC GGG GGA TTT ATT GTA	1152
Lys Val Gly His Val Gln Tyr Phe Leu Ala Leu Gly Gly Phe Ile Val	
370 375 380	
GCA TAT CAG CCT GTT CTA TCC AAA TCC CTG GCT CAT ATG TAC CTC AGA	1200
Ala Tyr Gln Pro Val Leu Ser Lys Ser Leu Ala His Met Tyr Leu Arg	
385 390 395 400	
GAA TTG ATG AGA GAC AAC AGG ACC GAT GAG ATG CTC GAC CTG GTA AAC	1248
Glu Leu Met Arg Asp Asn Arg Thr Asp Glu Met Leu Asp Leu Val Asn	
405 410 415	
AAT AAG CAT GCA ATT TAT AAG AAA AAT GCT ACC TCA TTG TCA CGA TTG	1296
Asn Lys His Ala Ile Tyr Lys Lys Asn Ala Thr Ser Leu Ser Arg Leu	
420 425 430	
CGG CGA GAT ATT CGA AAT GCA CCA AAT AGA AAA ATA ACA TTA GAC GAC	1344
Arg Arg Asp Ile Arg Asn Ala Pro Asn Arg Lys Ile Thr Leu Asp Asp	
435 440 445	
ACC ACA GCT ATT AAA TCG ACA TCG TCT GTT CAA TTC GCC ATG CTC CAA	1392
Thr Thr Ala Ile Lys Ser Thr Ser Ser Val Gln Phe Ala Met Leu Gln	
450 455 460	
TTT CTT TAT GAT CAT ATA CAA ACC CAT ATT AAT GAT ATG TTT AGT AGG	1440
Phe Leu Tyr Asp His Ile Gln Thr His Ile Asn Asp Met Phe Ser Arg	
465 470 475 480	

ATT GCC ACA GCT TGG TGC GAA TTG CAG AAT AGA GAA CTT GTT TTA TGG 1488
 Ile Ala Thr Ala Trp Cys Glu Leu Gln Asn Arg Glu Leu Val Leu Trp
 485 490 495
 CAC GAA GGG ATA AAG ATT AAT CCT AGC GCT ACA GCG AGT GCA ACA TTA 1536
 His Glu Gly Ile Lys Ile Asn Pro Ser Ala Thr Ala Ser Ala Thr Leu
 500 505 510
 GGA AGG AGA GTG GCT GCA AAG ATG TTG GGG GAT GTC GCT GCT GTA TCG 1584
 Gly Arg Arg Val Ala Ala Lys Met Leu Gly Asp Val Ala Ala Val Ser
 515 520 525
 AGC TGC ACT GCT ATA GAT GCG GAA TCC GTC ACT TTG CAA AAT TCT ATG 1632
 Ser Cys Thr Ala Ile Asp Ala Glu Ser Val Thr Leu Gln Asn Ser Met
 530 535 540
 CGA GTT ATC ACA TCC ACT AAT ACA TGT TAT AGC CGA CCA TTG GTT CTA 1680
 Arg Val Ile Thr Ser Thr Asn Thr Cys Tyr Ser Arg Pro Leu Val Leu
 545 550 555 560
 TTT TCA TAT GGA GAA AAC CAA GGA AAC ATA CAG GGA CAA CTC GGT GAA 1728
 Phe Ser Tyr Gly Glu Asn Gln Gly Asn Ile Gln Gly Gln Leu Gly Glu
 565 570 575
 AAC AAC GAG TTG CTT CCA ACG CTA GAG GCT GTA GAG CCA TGC TCG GCT 1776
 Asn Asn Glu Leu Leu Pro Thr Leu Glu Ala Val Glu Pro Cys Ser Ala
 580 585 590
 AAT CAT CGT AGA TAT TTT CTG TTT GGA TCC GGT TAT GCT TTA TTT GAA 1824
 Asn His Arg Arg Tyr Phe Leu Phe Gly Ser Gly Tyr Ala Leu Phe Glu
 595 600 605
 AAC TAT AAT TTT GTT AAG ATG GTA GAC GCT GCC GAT ATA CAG ATT GCT 1872
 Asn Tyr Asn Phe Val Lys Met Val Asp Ala Ala Asp Ile Gln Ile Ala
 610 615 620

AAT TTA GAA TCA GCC ATC AAC CAA GCT AAT ACG GAT AAA ACG ACT TTT 2352
 Asn Leu Glu Ser Ala Ile Asn Gln Ala Asn Thr Asp Lys Thr Thr Phe
 770 775 780
 GAT AAT GAA CAC CCA AAT TTA GTT GAA GCA TAC AAA GCA CTA AAA ACC 2400
 Asp Asn Glu His Pro Asn Leu Val Glu Ala Tyr Lys Ala Leu Lys Thr
 785 790 795 800
 ACT TTA GAA CAA CGT GCT ACT AAC CTT GAA GGT TTG TCA TCA ACT GCT 2448
 Thr Leu Glu Gln Arg Ala Thr Asn Leu Glu Gly Leu Ser Ser Thr Ala
 805 810 815
 TAT AAT CAA ATT CGC AAT AAT TTA GTG GAT CTA TAC AAT AAA GCT AGT 2496
 Tyr Asn Gln Ile Arg Asn Asn Leu Val Asp Leu Tyr Asn Lys Ala Ser
 820 825 830
 AGT TTA ATA ACT AAA ACA CTA GAT CCA CTA AAT GGG GGA ACG CTT TTA 2544
 Ser Leu Ile Thr Lys Thr Leu Asp Pro Leu Asn Gly Gly Thr Leu Leu
 835 840 845
 GAT TCT AAT GAG ATT ACT ACA GCT AAT AAG AAT ATT AAT AAT ACG TTA 2592
 Asp Ser Asn Glu Ile Thr Thr Ala Asn Lys Asn Ile Asn Asn Thr Leu
 850 855 860
 TCA ACT ATT AAT GAA CAA AAG ACT AAT GCT GAT GCA TTA TCT AAT AGT 2640
 Ser Thr Ile Asn Glu Gln Lys Thr Asn Ala Asp Ala Leu Ser Asn Ser
 865 870 875 880
 TTT ATT AAA AAA GTG ATT CAA AAT AAT GAA CAA AGT TTT GTA GGG ACT 2688
 Phe Ile Lys Lys Val Ile Gln Asn Asn Glu Gln Ser Phe Val Gly Thr
 885 890 895
 TTT ACA AAC GCT AAT GTT CAA CCT TCA AAC TAC AGT TTT GTT GCT TTT 2736
 Phe Thr Asn Ala Asn Val Gln Pro Ser Asn Tyr Ser Phe Val Ala Phe
 900 905 910

00470521040500
 0000000000000000

AGT GCT GAT GTA ACA CCC GTC AAT TAT AAA TAT GCA AGA AGG ACC GTT	2784
Ser Ala Asp Val Thr Pro Val Asn Tyr Lys Tyr Ala Arg Arg Thr Val	
915 920 925	
TGG AAT GGT GAT GAA CCT TCA AGT AGA ATT CTT GCA AAC ACG AAT AGT	2832
Trp Asn Gly Asp Glu Pro Ser Ser Arg Ile Leu Ala Asn Thr Asn Ser	
930 935 940	
ATC ACA GAT GTT TCT TGG ATT TAT AGT TTA GCT GGA ACA AAC ACG AAG	2880
Ile Thr Asp Val Ser Trp Ile Tyr Ser Leu Ala Gly Thr Asn Thr Lys	
945 950 955 960	
TAC CAA TTT AGT TTT AGC AAC TAT GGT CCA TCA ACT GGT TAT TTA TAT	2928
Tyr Gln Phe Ser Phe Ser Asn Tyr Gly Pro Ser Thr Gly Tyr Leu Tyr	
965 970 975	
TTC CCT TAT AAG TTG GTT AAA GCA GCT GAT GCT AAT AAC GTT GGA TTA	2976
Phe Pro Tyr Lys Leu Val Lys Ala Ala Asp Ala Asn Asn Val Gly Leu	
980 985 990	
CAA TAC AAA TTA AAT AAT GGA AAT GTT CAA CAA GTT GAG TTT GCC ACT	3024
Gln Tyr Lys Leu Asn Asn Gly Asn Val Gln Gln Val Glu Phe Ala Thr	
995 1000 1005	
TCA ACT AGT GCA AAT AAT ACT ACA GCT AAT CCA ACT CCA GCA GTT GAT	3072
Ser Thr Ser Ala Asn Asn Thr Thr Ala Asn Pro Thr Pro Ala Val Asp	
1010 1015 1020	
GAG ATT AAA GTT GCT AAA ATC GTT TTA TCA GGT TTA AGA TTT GGC CAA	3120
Glu Ile Lys Val Ala Lys Ile Val Leu Ser Gly Leu Arg Phe Gly Gln	
1025 1030 1035 1040	
AAC ACA ATC GAA TTA AGT GTT CCA ACG GGT GAA GGA AAT ATG AAT AAA	3168
Asn Thr Ile Glu Leu Ser Val Pro Thr Gly Glu Gly Asn Met Asn Lys	
1045 1050 1055	

GTT GCG CCA ATG ATT GGC AAC ATT TAT CTT AGC TCA AAT GAA AAT AAT 3216
Val Ala Pro Met Ile Gly Asn Ile Tyr Leu Ser Ser Asn Glu Asn Asn

1060

1065

1070

GCT GAT AAG ATC CCC GGG TAC CGT CGA CCC GGT ACA TTT TTA TAA 3261
Ala Asp Lys Ile Pro Gly Tyr Arg Arg Pro Gly Thr Phe Leu ***

1075

1080

1085

00447032-040300

SEQUENCE LISTING

SEQ NO: 4

Length of sequence: 1086

Type of sequence: amino acid

5 Topology: linear

Kind of sequence: protein

Sequence:

Met	His	Tyr	Phe	Arg	Arg	Asn	Cys	Ile	Phe	Phe	Leu	Ile	Val	Ile	Leu
1					5					10				15	
Tyr	Gly	Thr	Asn	Ser	Ser	Pro	Ser	Thr	Gln	Asn	Val	Thr	Ser	Arg	Glu
			20					25					30		
Val	Val	Ser	Ser	Val	Gln	Leu	Ser	Glu	Glu	Glu	Ser	Thr	Phe	Tyr	Leu
			35				40						45		
Cys	Pro	Pro	Pro	Val	Gly	Ser	Thr	Val	Ile	Arg	Leu	Glu	Pro	Pro	Arg
		50					55				60				
Lys	Cys	Pro	Glu	Pro	Arg	Lys	Ala	Thr	Glu	Trp	Gly	Glu	Gly	Ile	Ala
	65					70				75				80	
Ile	Leu	Phe	Lys	Glu	Asn	Ile	Ser	Pro	Tyr	Lys	Phe	Lys	Val	Thr	Leu
					85					90				95	
Tyr	Tyr	Lys	Asn	Ile	Ile	Gln	Thr	Thr	Thr	Trp	Thr	Gly	Thr	Thr	Tyr
			100						105					110	

Asp Pro Asn Arg Ile Ile Leu Gly Gln Cys Ile Lys Arg Glu Ala Glu
 340 345 350
 Ala Ala Ile Glu Gln Ile Phe Arg Thr Lys Tyr Asn Asp Ser His Val
 355 360 365
 Lys Val Gly His Val Gln Tyr Phe Leu Ala Leu Gly Gly Phe Ile Val
 370 375 380
 Ala Tyr Gln Pro Val Leu Ser Lys Ser Leu Ala His Met Tyr Leu Arg
 385 390 395 400
 Glu Leu Met Arg Asp Asn Arg Thr Asp Glu Met Leu Asp Leu Val Asn
 405 410 415
 Asn Lys His Ala Ile Tyr Lys Lys Asn Ala Thr Ser Leu Ser Arg Leu
 420 425 430
 Arg Arg Asp Ile Arg Asn Ala Pro Asn Arg Lys Ile Thr Leu Asp Asp
 435 440 445
 Thr Thr Ala Ile Lys Ser Thr Ser Ser Val Gln Phe Ala Met Leu Gln
 450 455 460
 Phe Leu Tyr Asp His Ile Gln Thr His Ile Asn Asp Met Phe Ser Arg
 465 470 475 480
 Ile Ala Thr Ala Trp Cys Glu Leu Gln Asn Arg Glu Leu Val Leu Trp
 485 490 495
 His Glu Gly Ile Lys Ile Asn Pro Ser Ala Thr Ala Ser Ala Thr Leu
 500 505 510
 Gly Arg Arg Val Ala Ala Lys Met Leu Gly Asp Val Ala Ala Val Ser
 515 520 525
 Ser Cys Thr Ala Ile Asp Ala Glu Ser Val Thr Leu Gln Asn Ser Met
 530 535 540
 Arg Val Ile Thr Ser Thr Asn Thr Cys Tyr Ser Arg Pro Leu Val Leu
 545 550 555 560

Phe Ser Tyr Gly Glu Asn Gln Gly Asn Ile Gln Gly Gln Leu Gly Glu
 565 570 575
 Asn Asn Glu Leu Leu Pro Thr Leu Glu Ala Val Glu Pro Cys Ser Ala
 580 585 590
 Asn His Arg Arg Tyr Phe Leu Phe Gly Ser Gly Tyr Ala Leu Phe Glu
 595 600 605
 Asn Tyr Asn Phe Val Lys Met Val Asp Ala Ala Asp Ile Gln Ile Ala
 610 615 620
 Ser Thr Phe Val Glu Leu Asn Leu Thr Leu Leu Glu Asp Arg Glu Ile
 625 630 635 640
 Leu Pro Leu Ser Val Tyr Thr Lys Glu Glu Leu Arg Asp Val Gly Val
 645 650 655
 Leu Asp Tyr Ala Glu Val Ala Arg Arg Asn Gln Leu His Glu Leu Lys
 660 665 670
 Phe Tyr Asp Ile Asn Lys Val Ile Glu Val Asp Thr Asn Tyr Ala Gly
 675 680 685
 Leu Gln Glu Phe Gly Cys Met Ser Ile Thr Lys Lys Asp Ala Asn Pro
 690 695 700
 Asn Asn Gly Gln Thr Gln Leu Glu Ala Ala Arg Met Glu Leu Thr Asp
 705 710 715 720
 Leu Ile Asn Ala Lys Ala Met Thr Leu Ala Ser Leu Gln Asp Tyr Ala
 725 730 735
 Lys Ile Glu Ala Ser Leu Ser Ser Ala Tyr Ser Glu Ala Glu Thr Val
 740 745 750
 Asn Asn Asn Leu Asn Ala Thr Leu Glu Gln Leu Lys Met Ala Lys Thr
 755 760 765
 Asn Leu Glu Ser Ala Ile Asn Gln Ala Asn Thr Asp Lys Thr Thr Phe
 770 775 780

0
4
4
7
0
5
2
1
0
4
0
5
0
0

Asp Asn Glu His Pro Asn Leu Val Glu Ala Tyr Lys Ala Leu Lys Thr			
785	790	795	800
Thr Leu Glu Gln Arg Ala Thr Asn Leu Glu Gly Leu Ser Ser Thr Ala			
805	810	815	
Tyr Asn Gln Ile Arg Asn Asn Leu Val Asp Leu Tyr Asn Lys Ala Ser			
820	825	830	
Ser Leu Ile Thr Lys Thr Leu Asp Pro Leu Asn Gly Gly Thr Leu Leu			
835	840	845	
Asp Ser Asn Glu Ile Thr Thr Ala Asn Lys Asn Ile Asn Asn Thr Leu			
850	855	860	
Ser Thr Ile Asn Glu Gln Lys Thr Asn Ala Asp Ala Leu Ser Asn Ser			
865	870	875	880
Phe Ile Lys Lys Val Ile Gln Asn Asn Glu Gln Ser Phe Val Gly Thr			
885	890	895	
Phe Thr Asn Ala Asn Val Gln Pro Ser Asn Tyr Ser Phe Val Ala Phe			
900	905	910	
Ser Ala Asp Val Thr Pro Val Asn Tyr Lys Tyr Ala Arg Arg Thr Val			
915	920	925	
Trp Asn Gly Asp Glu Pro Ser Ser Arg Ile Leu Ala Asn Thr Asn Ser			
930	935	940	
Ile Thr Asp Val Ser Trp Ile Tyr Ser Leu Ala Gly Thr Asn Thr Lys			
945	950	955	960
Tyr Gln Phe Ser Phe Ser Asn Tyr Gly Pro Ser Thr Gly Tyr Leu Tyr			
965	970	975	
Phe Pro Tyr Lys Leu Val Lys Ala Ala Asp Ala Asn Asn Val Gly Leu			
980	985	990	
Gln Tyr Lys Leu Asn Asn Gly Asn Val Gln Gln Val Glu Phe Ala Thr			
995	1000	1005	

Ser Thr Ser Ala Asn Asn Thr Thr Ala Asn Pro Thr Pro Ala Val Asp
 1010 1015 1020
 Glu Ile Lys Val Ala Lys Ile Val Leu Ser Gly Leu Arg Phe Gly Gln
 1025 1030 1035 1040
 Asn Thr Ile Glu Leu Ser Val Pro Thr Gly Glu Gly Asn Met Asn Lys
 1045 1050 1055
 Val Ala Pro Met Ile Gly Asn Ile Tyr Leu Ser Ser Asn Glu Asn Asn
 1060 1065 1070
 Ala Asp Lys Ile Pro Gly Tyr Arg Arg Pro Gly Thr Phe Leu ***
 1075 1080 1085

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199